{'fraction_non_alphanumeric': 0.02490842490842491, 'fraction_numerical': 0.011721611721611722, 'mean_word_length': 5.324074074074074, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
A review of pyridine and pyrimidine derivatives as anti-MRSA agents



Methicillin-resistant Staphylococcus aureus (MRSA) is a gram-positive strain whose resistance against existing antibiotics is a major concern for the researchers across the globe. Gram-positive infections, particularly methicillin-resistant Staphylococcus aureus spreading among S. aureus isolates, observed to increase exponentially from 29% in 2009 to 47% in 2014. Literature reviews revealed about 13-74% of worldwide S. aureus strains are Methicillin-resistant.



In this article, we have summarized the mechanism of bacterium resistance, molecular targets to treat MRSA, and the activity of reported pyridine and pyrimidine derivatives against methicillin-resistant Staphylococcus aureus.



The data collected for this study from online peer reviewed research articles and Molecular-docking study of reported anti-MRSA agents performed by using Maestro Module of Schrodinger software. Results of in silico studies showed that some pyridine derivatives having better binding interactions than standard anti-MRSA agents.



Molecular docking studies of reported pyridine derivatives resulted in excellent hits for the development of novel anti- MRSA agents. Overall, this study will be immense importance for researchers working in design and development of target based anti-MRSA agents.
